1. BSRBR-RA UK CRN ID: 7302 July 2014 update

2. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab Can be re-registered if already on the study Tocilizumab Must have diagnosis of RA Must be registered within 6 months of first dose of IV or S/C tocilizumab Can be re-registered if already on the study Anti-TNF Comparison Cohort Must have diagnosis of RA Must be registered within 6 months of first dose of etanercept, adalimumab or infliximab Numbers recruited up to 30/06/2014 854 As of 30/06/2014 956 As of 30/06/2014 720 As of 30/06/2014

3. Recruitment over the last year Certolizumab recruitment by month (1 July 2013 – 30 June 2014) Tocilizumab recruitment by month (1 July 2013 – 30 June 2014) Anti-TNF cohort recruitment by month (1 July 2013 – 30 June 2014)

4. Recruitment 01/01/2014 – 30/06/2014

5. BSR Region Awards January 2014 – July 2014 North West East of England West Midlands 69 56 50 East Midlands

6. Recent BSRBR-RA publications – Risk of solid cancer in patients exposed to anti-TNF therapy: results from the BSRBR-RA. Mercer, L., Lunt, M., Low, A., Dixon, W., Watson, K., Symmons, D. &Hyrich, K (2014). Ann Rheum Dis, [Epub ahead of print] -Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. McErlane F, Foster HE, Davies R, Lunt M, Watson KD, Symmons DP, Hyrich KL. (2013) Rheumatology (Oxford), [Epub ahead of print] – The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Závada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K. & (2013). Ann Rheum Dis, [Epub ahead of print]

7. Accessing BSRBR-RA data You can access data from the BSRBR-RA via a “third party data request form” (contact ARoach@rheumatology.org.uk for a copy). ARoach@rheumatology.org.uk Proposals should be discussed with Kath.watson@manchester.ac.uk Kath.watson@manchester.ac.uk Kimme.hyrich@manchester.ac.uk in advance of submission to discuss feasibility. Proposals can be submitted at any time of the year – there are no submission deadlines. http://www.rheumatology.org.uk/resources/bsr_biologics_registers/

8. Recent/ongoing research projects via the BSRBR-RA data access scheme  Non-inflammatory pain mechanisms as confounders in the clinical assessment of synovitis in RA  Study of fatigue in inflammatory arthritis  Effectiveness of TNF response define by season of initiation of therapy, with particular focus on vitamin D  To explore the influence of gender and gender-related variables on severity of prognosis for RA  Obesity and clinical response to anti-TNF medication

9. Contacts Email: biologics.register@manchester.ac.ukbiologics.register@manchester.ac.uk Tel: 0161 275 1652/7390 Web: http://man.ac.uk/mS3HTm Twitter: @BSRBR_RA

10. Acknowledgements UK Consultant Rheumatologists and Specialist Nurses UK Comprehensive Research Networks BSRBR-RA Control Centre Consortium British Society for Rheumatology Arthritis Research UK Centre for Epidemiology, Manchester